SEER Jumps As CEO Buyout Bid Collides With Activists

Seer Inc. surged as investors cheered its most impactful breakthrough news, with stocks have been trading up by 41.1 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading SEER

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Activist investors holding about 7.7% of Seer are urging shareholders to replace the chair/CEO and two directors after a roughly 97% share price decline since the 2020 IPO and over $465M in losses.
The activists allege the board rejected three premium acquisition offers and ignored a settlement proposal with governance reforms and a sizable tender offer, while seeing profitability only by 2031 under current leadership.
A management buyout proposal from chair and CEO Omid Farokhzad would take Seer Inc. private at $2.45 per share plus two CVRs, now under review by an independent Special Committee.
A favorable European Patent Office ruling and a U.S. ITC investigation against Nanomics strengthen SEER’s intellectual property around the Proteograph platform.
Preliminary Korea University data suggest the Proteograph Product Suite, combined with an ID-free AI framework, may support future multi-cancer screening across ten major cancer types.

Weekly Update Jun 29 – Jul 03, 2026: On Sunday, July 05, 2026 Seer Inc. stock [NASDAQ: SEER] is trending up by 41.1%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

Seer occupies a niche position in proteomics with differentiated IP but remains fundamentally an early‑stage, subscale platform story. Revenue at ~$16.6m with ~49% gross margin is overshadowed by extreme negative EBIT margins (over ‑400%) and persistent losses (Q1 net loss ~$16.8m). Operating cash burn of ~$15m in the quarter implies less than three years of runway, even with ~$167m in cash and investments. Leverage is modest and liquidity strong, but returns on capital are deeply negative.

Technically, the stock has undergone a violent repricing: flat around $1.63–1.67 before a high‑volume spike to $2.34 and close at $2.30, clearly driven by the $2.45 take‑private headline. The dominant trend near term is bullish but event‑driven and crowded, with intraday 5‑minute candles showing repeated fades above $2.30 as arbitrage players cap upside. $2.45 is now the decisive trading level; entries sub‑$2.10 with exits $2.35–2.40 favor a merger‑arb, not long‑term, setup.

More Breaking News

Catalysts are now overwhelmingly governance and M&A‑driven. The CEO’s $2.45‑plus‑CVR bid, activist pressure citing a 97% drawdown, rejected prior premium offers, and a newly empowered special committee together frame Seer as a contested asset rather than a standalone growth comp. Relative to loss‑making proteomics peers, Seer screens worse on revenue scale and burn but better on IP defense. Base case is a transaction at or modestly above $2.45; I see downside support near $1.80 and resistance at $2.60.

Quick Financial Overview

SEER’s chart just flashed a sharp shift in sentiment. After grinding around $1.63–$1.67 in late June, the stock spiked to an intraday high above $2.34 on 2026/07/02 and closed near $2.30. That jump lines up with the management buyout proposal at $2.45 per share plus contingent value rights, effectively resetting trader focus toward deal odds rather than standalone fundamentals.

The intraday action shows a classic rerating move: a prior 5-minute candle had SEER pinned around the mid-$1.50s to low-$1.60s, then news drove a vertical repricing. For short-term traders, that $1.60 area now marks the pre-deal base, while the $2.45 headline price becomes the obvious reference cap until the Special Committee gives guidance. Any pullbacks toward $2.00–$2.10 will likely be read as the market handicapping deal risk.

Under the surface, Seer Inc. remains a high-burn, early-revenue story. Quarterly revenue is about $2.79M, with annualized revenue near $16.58M and gross margin near 49.4%, but profitability is far off: EBIT margin is roughly -465%, and profit margin around -458%. Cash flow from operations for the latest quarter was about -$15.44M, with free cash flow at roughly -$15.71M, yet the balance sheet shows strength: cash and short-term investments total about $166.67M, current ratio is 17.7, and debt is modest with total debt-to-equity around 0.1.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!